Safety and effectiveness of isavuconazole in real-life non-neutropenic patients

Objectives Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods A retrospective, observational m...

Descripción completa

Detalles Bibliográficos
Autores: Monzó-Gallo, Patricia, Lopera, Carlos, Badía-Tejero, Ana M., Machado, Marina, García-Rodríguez, Julio, Vidal-Cortés, Pablo, Merino, Esperanza, Calderón, Jorge, Fortún, Jesús, Palacios-Baena, Zaira Raquel, Pemán, Javier, Sanchis, Joan Roig, Aguilar-Guisado, Manuela, Gudiol, Carlota, Ramos, Juan C., Sánchez-Romero, Isabel, Martín-Dávila, Pilar, López-Cortés, Luis Eduardo, Salavert, Miguel, Ruiz-Camps, Isabel, Chumbita, Mariana, Aiello, Tommaso Francesco, Peyrony, Olivier, Puerta-Alcalde, Pedro, Soriano, Alex, Marco, Francesc, Garcia-Vidal, Carolina
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/386465
Acceso en línea:http://hdl.handle.net/10261/386465
https://api.elsevier.com/content/abstract/scopus_id/85193035853
Access Level:acceso abierto
Palabra clave:Effectiveness
Invasive fungal infection
Isavuconazole
Non-neutropenic
Safety
Descripción
Sumario:Objectives Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. Results A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Conclusion Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported.

Similares en LA Referencia